Tenpoint Therapeutics, Inc. announces positive topline data from BRIO-II study for BRIMOCHOL™ PF to treat presbyopia.
Jan 09, 2025
SeattleBiotechnologyHealth CareTherapeutics
Product Description
Tenpoint Therapeutics, Inc. has reported positive topline results from its Phase 3 pivotal trial for BRIMOCHOL™ PF, demonstrating significant improvements in near vision and pupil size reduction without serious adverse events over a 12-month period.
Company Information
Company
Tenpoint Therapeutics
Location
Seattle, Washington, United States
About
Tenpoint is a biotechnology company committed to advancing engineered cell-based therapies and in vivo reprogramming to restore vision for people with degenerative ocular diseases, bringing together the global experts who are shaping the regenerative ocular medicine revolution and the technologies that are driving it. We are addressing the ultimate cause of vision loss by replacing diseased cells with healthy ones to permanently restore vision. Tenpoint’s global team is united by our passion for science and our commitment to patients.
Fundz sees it the moment Tenpoint Therapeutics ships something new, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
SeattleBiotechnologyHealth CareTherapeutics